These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26288848)

  • 21. Statin use and non-alcoholic steatohepatitis in at risk individuals.
    Dongiovanni P; Petta S; Mannisto V; Mancina RM; Pipitone R; Karja V; Maggioni M; Kakela P; Wiklund O; Mozzi E; Grimaudo S; Kaminska D; Rametta R; Craxi A; Fargion S; Nobili V; Romeo S; Pihlajamaki J; Valenti L
    J Hepatol; 2015 Sep; 63(3):705-12. PubMed ID: 25980762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study.
    Pasta A; Borro P; Cremonini AL; Formisano E; Tozzi G; Cecchi S; Fresa R; Labanca S; Djahandideh A; Sukkar SG; Picciotto A; Pisciotta L
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00820. PubMed ID: 34476902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis?
    Gravito-Soares M; Gravito-Soares E; Gomes D; Tome L
    Ann Hepatol; 2019; 18(1):78-88. PubMed ID: 31113613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
    van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
    Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease.
    Yeniova AO; Küçükazman M; Ata N; Dal K; Kefeli A; Başyiğit S; Aktaş B; Ağladioğlu K; Akin KO; Ertugrul DT; Nazligül Y; Beyan E
    Hepatogastroenterology; 2014; 61(130):422-5. PubMed ID: 24901154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet.
    Lopresti MW; Cui W; Abernathy BE; Fredrickson G; Barrow F; Desai AS; Revelo XS; Mashek DG
    J Lipid Res; 2021; 62():100133. PubMed ID: 34624333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysosomal Acid Lipase Activity: A Tool for the Detection and Management of Fatty Liver Disease?
    Ramirez CM; Lopez AM; Turley SD
    EBioMedicine; 2015 Jul; 2(7):638-9. PubMed ID: 26286464
    [No Abstract]   [Full Text] [Related]  

  • 33. Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes.
    Bi WR; Yang CQ; Shi Q; Xu Y; Cao CP; Ling J; Wang XY
    Genet Mol Res; 2014 Aug; 13(3):5880-91. PubMed ID: 25117346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
    Imajo K; Hyogo H; Yoneda M; Honda Y; Kessoku T; Tomeno W; Ogawa Y; Taguri M; Mawatari H; Nozaki Y; Fujita K; Kirikoshi H; Saito S; Sumida Y; Ono M; Wada K; Nakajima A; Eguchi Y
    PLoS One; 2014; 9(12):e115403. PubMed ID: 25541989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients.
    Pavanello C; Baragetti A; Branchi A; Grigore L; Castelnuovo S; Giorgio E; Catapano AL; Calabresi L; Gomaraschi M
    Pharmacol Res; 2019 Sep; 147():104362. PubMed ID: 31330253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity.
    Zhu WH; Fang LZ; Lu CR; Dai HL; Chen JH; Qiao QH; Chen LY
    World J Gastroenterol; 2015 Sep; 21(35):10192-9. PubMed ID: 26401084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.
    Pastori D; Pani A; Di Rocco A; Menichelli D; Gazzaniga G; Farcomeni A; D'Erasmo L; Angelico F; Del Ben M; Baratta F
    Br J Clin Pharmacol; 2022 Feb; 88(2):441-451. PubMed ID: 34133035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
    Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
    Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH).
    Sekhon AK; Gollapalli A; Kaur D; Janssen B; Stevens ML; Valerio F; Sierra-Hoffman MA
    Am J Case Rep; 2021 Nov; 22():e932961. PubMed ID: 34826302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.
    Pastori D; Polimeni L; Baratta F; Pani A; Del Ben M; Angelico F
    Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.